According to a study by Boston Consulting Group (BCG), Multinational Pharmaceutical Companies (MPCs) are increasingly exploring India and China as they are seeking various offshoring options for their R&D function.
The upcoming trend is attributed to the improving regulatory and competitive environment in the two countries. Amongst the findings, almost all the top 20 MPCs have outsourced their chemistry work to China.
The report states that the MPCs wishing to establish successful offshore R&D operations in India and China should adopt an integrated strategy, as against the ad-hoc strategies which are currently being followed by some of the companies operating in the domain.
The offshoring strategy should be flexible enough to incorporate the changes in the R&D capabilities of the two countries.
Take the marketing executive in Manhattan, who works with the statistical researcher in Moscow to analyze the behaviors of customer in London. She directs manufacturing in Shanghai to modify production based on the findings – all using the information systems constantly being improved by software engineers in Bangalore.... Call it partnering, teaming, cooperation, or collaboration – just don’t call it outsourcing. Global teamwork is more like it.
Surgen General's Disclimar
The opinions on this site are those of the individual author, unless otherwise attributed, and do not necessarily represent the opinions of the author's employer.
No comments:
Post a Comment